Limited data exist on the impact of the introduction of newer selective cyclo-oxygenase-2 (COX-2) inhibitors into clinical practice in 1999.
|Hospitalization decreased from 17 to 12 per 100,000 person-years|
|Alimentary Pharmacology & Therapeutics|
There is little data on overall non-steroidal anti-inflammatory drug (NSAID) use and hospitalization rates of complicated peptic ulcer disease at the population level.
Dr Christensen and colleagues from Denmark examined these issues, and conducted a population-based study.
The research team identified 1488 patients with perforated and 6017 with bleeding peptic ulcers between 1996 and 2004 in hospital discharge registries.
The team computed standardized annual hospitalization rates and hospitalization rate ratios using Poisson regression.
Data on annual number of prescriptions for non-steroidal anti-inflammatory drugs were obtained through population-based prescription databases.
The introduction of newer selective cyclo-oxygenase-2 inhibitors was followed by a 44% increase in the annual number of prescriptions for NSAIDs.
The researchers found that this increase was almost entirely due to increased use of newer selective cyclo-oxygenase-2 inhibitors.
The team observed that annual standardized hospitalization rates for bleeding peptic ulcer remained stable.
Standardized hospitalization rates for perforated peptic ulcer decreased from 17 per 100,000 person-years in 1996 to 12 per 100,000 person-years in 2004.
Dr Christensen's team concluded, “Introduction of newer selective cyclo-oxygenase-2 inhibitors was followed by substantial increase in overall non-steroidal anti-inflammatory drug use. “
“This coincides with stable and decreasing hospitalization rates for bleeding and perforated peptic ulcer, respectively.”